Valerio Therapeutics Société anonyme (ALVIO.PA)

EUR 0.08

(3.31%)

Market Cap (In EUR)

12 Million

Revenue (In EUR)

1.8 Million

Net Income (In EUR)

-20.34 Million

Avg. Volume

47.36 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.065-0.1715
PE
-
EPS
-
Beta Value
1.718
ISIN
FR0010095596
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Shefali Agarwal M.D., MPH
Employee Count
-
Website
https://valeriotx.com
Ipo Date
2023-06-05
Details
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.